Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The protein encoded by S100A2 is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. Zusätzlich bieten wir Ihnen S100A2 Antikörper (40) und S100A2 Kits (13) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 16 products:
Human S100A2 Protein expressed in Human Cells - ABIN2002264
Lapi, Iovino, Fontemaggi, Soliera, Iacovelli, Sacchi, Rechavi, Givol, Blandino, Strano: S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. in Oncogene 2006
Zeige alle 5 Referenzen für ABIN2002264
Human S100A2 Protein expressed in Escherichia coli (E. coli) - ABIN2002266
Gimona, Lando, Dolginov, Vandekerckhove, Kobayashi, Sobieszek, Helfman: Ca2+-dependent interaction of S100A2 with muscle and nonmuscle tropomyosins. in Journal of cell science 1997
Zeige alle 5 Referenzen für ABIN2002266
Human S100A2 Protein expressed in Escherichia coli (E. coli) - ABIN667377
Nagy, Brenner, Markadieu, Chaboteaux, Camby, Schäfer, Pochet, Heizmann, Salmon, Kiss, Decaestecker: S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. in Laboratory investigation; a journal of technical methods and pathology 2001
Zeige alle 2 Referenzen für ABIN667377
These results indicate that oxidative stress impairs the ability of S100 proteins to bind and activate PP5 (zeige PPP5C Proteine), which in turn modulates the ASK1 (zeige MAP3K5 Proteine)-mediated signaling cascades involved in apoptosis.
high S100A2 expression and NSCLC
Our results indicate that serum levels of S100A2 and S100A6 (zeige S100A6 Proteine) are significantly elevated in early stage non-small cell lung cancer
S100A2 could have a role in poor prognosis in stage II and III colorectal cancer recurrence
The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients.
Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target.
Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs.
These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53 (zeige TP53 Proteine).
loss of S100A2 expression contributes to Ggastric cancer development and progression.
S100A2 protumorigenic actions and its involvement in TGF-beta (zeige TGFB1 Proteine)-mediated cancer cell invasion and epithelial-mesenchymal transition.
S100A2 and S100A6 (zeige S100A6 Proteine) interact with another TPR (zeige GRID2 Proteine) protein Tom70 (zeige TOMM70A Proteine) and regulate the Tom70 (zeige TOMM70A Proteine)-ligand interaction in vitro
Survival after UVA irradiation was greater in human keratinocytes compared to mouse skin with no S100A2 expression, showing a protective role for S100A2. A S100A2-dependent difference was observed in the induction of Cxcl13 (zeige CXCL13 Proteine) transcripts in transgenic mice.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer.
S100 calcium binding protein A2
, S100 calcium-binding protein A2
, protein S100-A2
, predicted gene, EG628324